VEGFR-TKIs are associated with adverse outcomes, such as hypothyroidism, delayed wound healing, gastrointestinal perforation, and proteinuria, which are rarely reported with traditional anticancer drugs.7,8,9 Additionally, the VEGF pathway is involved in angiogenesis, endothelial cell integrity, and vascular tone, and so adverse outcomes, such as hypertension, arterial thromboembolism, and left ventricular dysfunction, have also been reported after treatment with VEGFR-TKIs.10,11,12,13. This evidence concerns the gene KDR and Hypertension.